Grijota-Martínez C et al. MCT8 deficiency: the road to therapies for a rare disease. Front. Neurosci. 2020:14:380. doi: 10.3389/fnins.2020.00380 . PMID: 32410949.
Groeneweg S et al. Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study," (in eng), Lancet Diabetes Endocrinol. 2020;8(7):594-605. PMID: 32559475. doi: 10.1016/S2213-8587(20)30153-4
Groeneweg S et al. Effectiveness and safety of the tri-iodothyronine analogue triac in children and adults with MCT8 deficiency: an international, single-arm, openlabel, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7(9):695–706. doi: 10.1016/S2213-8587(19)30155-X . PMID: 31377265.
Kubota M et al. A nationwide survey of monocarboxylate transporter 8 deficiency in Japan: Its incidence, clinical course, MRI and laboratory findings. Brain Dev. 2022;44(10):699-705. doi:10.1016/j.braindev.2022.07.007. PMID: 35945102.
Masnada S et al. Movement disorders in MCT8 deficiency/Allan-Herndon-Dudley Syndrome. Mol Genet Metab. 2022;135(1):109-113. doi: 10.1016/j.ymgme.2021.12.003. PMID: 34969638.
Remerand G et al. Expanding the phenotypic spectrum of Allan-Herndon-Dudley syndrome in patients with SLC16A2 mutations. (in eng), Dev Med Child Neurol. 2019;61(12):1439–1447. doi: 10.1111/dmcn.14332 . PMID: 34969638
Sarret C et al. Allan-Herndon-Dudley Syndrome. 2010 Mar 9 [updated 2020 Jan 16]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023.